UNSPSC 51262905: Prenalterol

This classification denotes an adrenergic beta-1 receptor agonist, cardiotonic agent, and sympathomimetic with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4G34404CX, chemically known as phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (s)- but generally known as prenalterol, which bears US NIH Compound Identifier 42396. European Medicines Agency schedules Prenalterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10027MIG.

UNSPSC 51262905 Prenalterol, a Commodity code, shows minimal recent activity aligned with its nominal pharmaceutical scope. The single recent opportunity tagged to this code — Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems — centers on procurement of finished pharmaceutical products for community health distribution, not prenalterol specifically. A second opportunity, the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs, addresses pharmacy benefit program structure and vendor capabilities rather than a specific drug product. State and local solicitations under this code remain sparse and do not reflect sustained demand for prenalterol as a line item.

Seminole County's naloxone procurement (IFB, response due July 26, 2023) sought 1,900 units annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year base contract with one-year renewal option and FEMA potential funding. The Texas HHS RFI (response due April 3, 2026) operated as exploratory market intelligence rather than a committed procurement, seeking vendor input on direct-to-manufacturer pharmacy models without specifying budget, award value, or formal evaluation criteria. Geographic activity centers on Florida and Texas, though the broader code shows no evident pattern of repeat buyers or concentrated procurement volume. Vendors pursuing this code should monitor for pharmaceutical product solicitations from county health departments and state health agencies, though current activity does not indicate robust or sustained contracting opportunity under the prenalterol classification.